FDA Inspection 1233201 — Novo Nordisk Pharmaceutical Industries LP
The FDA completed an inspection of Novo Nordisk Pharmaceutical Industries LP on December 20, 2023 in Durham, NC. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 20, 2023
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Durham, NC (United States)